Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2013 · 10-Q
Revenue$1.23M$1.23M+170.4% vs Q3 2012 Net Income-$411.73K-$411.73KN/M vs Q3 2012 EPS Diluted$0.00$0.00N/M vs Q3 2012 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$409,434N/M Free Cash Flowderived$409,434N/M Margins · derivedGross margin68.9%
Operating margin-11.6%+11.9 pt vs Q3 2012
Net margin-33.6%−10.2 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 14, 2013 · 45 d after period end